Loracarbef (LY163892) versus amoxicillin/clavulanate in bronchopneumonia and lobar pneumonia.

In a single-blind study, 134 patients with bronchopneumonia or lobar pneumonia were randomly assigned to receive 400 mg of loracarbef twice daily or 500/125 mg of amoxicillin/clavulanate three times daily for 10 to 14 days. Treatment efficacy was evaluated in 38 patients treated with loracarbef and in 39 treated with amoxicillin/clavulanate in whom pre-treatment positive cultures of pathogens susceptibile to the study drugs were isolated. Streptococcus pneumoniae and Haemophilus influenzae were cultured as single pathogens in 40.3% of the evaluable patients. Among the evaluable patients, 100% of the loracarbef group and 92.3% of the amoxicillin/clavulanate group had a favorable clinical response (cure or improvement). Bacteriologic response was favorable and the pathogen was eliminated or presumed eliminated in 97.4% of the loracarbef-treated patients and in 92.3% of the amoxicillin/clavulanate-treated patients. Treatment was discontinued in one loracarbef-treated patient because Ludwig's angina, unrelated to the study drug, was diagnosed and in five amoxicillin/clavulanate-treated patients because of diarrhea (two patients), rash (two patients), and nausea and vomiting (one patient). Diarrhea, the most frequently cited adverse event, was reported by 6.1% of the loracarbef-treated patients and 11.8% of the amoxicillin/clavulanate-treated patients. Asthenia was reported by 0% and 8.8% of the loracarbef and amoxicillin/clavulanate patients, respectively. It is concluded that both loracarbef and amoxicillin/clavulanate are safe and effective in the treatment of acute bacterial pneumonia.
AuthorsD L Hyslop, K Jacobson, F J Guerra
JournalClinical therapeutics (Clin Ther) 1992 Mar-Apr Vol. 14 Issue 2 Pg. 254-67 ISSN: 0149-2918 [Print] UNITED STATES
PMID1611648 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Cephalosporins
  • Clavulanic Acids
  • loracarbef
  • Amoxicillin-Potassium Clavulanate Combination
  • Amoxicillin
  • Amoxicillin (adverse effects, therapeutic use)
  • Amoxicillin-Potassium Clavulanate Combination
  • Bacterial Infections (drug therapy)
  • Bronchopneumonia (drug therapy)
  • Cephalosporins (adverse effects, therapeutic use)
  • Clavulanic Acids (adverse effects, therapeutic use)
  • Drug Therapy, Combination (adverse effects, therapeutic use)
  • Haemophilus Infections (drug therapy)
  • Haemophilus influenzae (isolation & purification)
  • Humans
  • Microbial Sensitivity Tests
  • Pneumonia, Pneumococcal (drug therapy)
  • Single-Blind Method
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: